69 related articles for article (PubMed ID: 2554509)
1. [Hormone treatments of advanced breast cancers].
Espie M
Soins; 1989; (526-527):6-8. PubMed ID: 2554509
[No Abstract] [Full Text] [Related]
2. Evaluation of estrogen dependency of human breast cancers. II. Clinical evaluation of tamoxifen in advanced primary and recurrent breast cancer.
Nishiki M; Yamane M; Amano K; Yasuda K; Okumichi T; Ezaki H
Hiroshima J Med Sci; 1984 Jun; 33(2):163-6. PubMed ID: 6480380
[No Abstract] [Full Text] [Related]
3. [Hormone therapy and chemotherapy of breast cancer].
Heuson JC; Mattheiem WH
Brux Med; 1976 Dec; 56(12):489-95. PubMed ID: 189879
[No Abstract] [Full Text] [Related]
4. [Management of surgically treated breast cancer with special reference to hormone receptors and hormone therapy].
Salzer H
Gynakol Rundsch; 1981; 21 Suppl 2():23-7. PubMed ID: 6274769
[No Abstract] [Full Text] [Related]
5. Megestrol acetate v tamoxifen in advanced breast cancer in postmenopausal patients.
Morgan LR
Semin Oncol; 1985 Mar; 12(1 Suppl 1):43-7. PubMed ID: 3975652
[TBL] [Abstract][Full Text] [Related]
6. The changing role of endocrine therapy in the management of advanced breast cancer.
Hayward JL
Eur J Cancer (1965); 1980; Suppl 1():81-2. PubMed ID: 6274641
[No Abstract] [Full Text] [Related]
7. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
Meijer-van Gelder ME; Look MP; Peters HA; Schmitt M; Brünner N; Harbeck N; Klijn JG; Foekens JA
Cancer Res; 2004 Jul; 64(13):4563-8. PubMed ID: 15231667
[TBL] [Abstract][Full Text] [Related]
8. Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PgR and AR) in patients with primary breast cancer.
Lundgren S; Søreide JA; Lea OA
Anticancer Res; 1994; 14(3B):1313-6. PubMed ID: 8067700
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
10. Concordance of the hormone receptors and correlation of HER-2/neu overexpression of the metachronous cancers of contralateral breasts.
Stark A; Lu M; Mackowiak P; Linden M
Breast J; 2005; 11(3):183-7. PubMed ID: 15871703
[TBL] [Abstract][Full Text] [Related]
11. [Hormone therapy in breast cancer].
Rouëssé J
Chirurgie; 1994-1995; 120(6-7):330-7. PubMed ID: 7768120
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of tamoxifen versus combined tamoxifen and diethylstilboestrol in advanced breast cancer in postmenopausal women.
Mouridsen HT; Salimtschik M; Dombernowsky P; Gelshoj K; Palshof T; Rorth M; Daehnfeldt JL; Rose C
Eur J Cancer (1965); 1980; Suppl 1():107-10. PubMed ID: 7032918
[No Abstract] [Full Text] [Related]
13. Rechallenging breast cancer with tamoxifen therapy.
Stoll BA
Clin Oncol; 1983 Dec; 9(4):347-51. PubMed ID: 6198122
[TBL] [Abstract][Full Text] [Related]
14. Progress in chemoprevention of breast cancer.
Serrano D; Perego E; Costa A; Decensi A
Crit Rev Oncol Hematol; 2004 Feb; 49(2):109-17. PubMed ID: 15012972
[TBL] [Abstract][Full Text] [Related]
15. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
[TBL] [Abstract][Full Text] [Related]
16. [Value of hormone therapy in metastasizing breast cancer].
Samonigg H
Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208
[TBL] [Abstract][Full Text] [Related]
17. Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.
Lorenz I; Mechl Z
Neoplasma; 1985; 32(1):119-24. PubMed ID: 3157070
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy monitored by hormone cytological examination in advanced female breast cancer.
Iglódi F
Ther Hung; 1989; 37(4):205-8. PubMed ID: 2631288
[TBL] [Abstract][Full Text] [Related]
19. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
Pannuti F; Martoni A; Fruet F; Strocchi E; Di Marco AR
Eur J Cancer (1965); 1980; Suppl 1():93-8. PubMed ID: 6459237
[No Abstract] [Full Text] [Related]
20. Invasiveness gene signature predicts a favorable outcome also in estrogen receptor-positive primary breast cancers treated with adjuvant tamoxifen.
Coradini D; Gariboldi M; Fedeli M; Pierotti MA; Daidone MG
Breast Cancer Res Treat; 2008 Sep; 111(2):389-90. PubMed ID: 17914668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
